| human | Q5 |
| P856 | official website | https://faculty.mdanderson.org/profiles/dipen_maru.html |
| P496 | ORCID iD | 0000-0002-9134-7709 |
| P1153 | Scopus author ID | 35254053800 |
| P108 | employer | The University of Texas MD Anderson Cancer Center | Q1525831 |
| P106 | occupation | researcher | Q1650915 |
| Q48729661 | 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. |
| Q36328330 | 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients |
| Q87238639 | A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer |
| Q37406693 | A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer |
| Q34961992 | A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. |
| Q91302125 | A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries |
| Q104794572 | ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer |
| Q64978553 | Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. |
| Q84522311 | Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma |
| Q33709855 | Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma |
| Q88906805 | Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma |
| Q94455510 | Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases |
| Q34824033 | Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience |
| Q49562156 | Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis |
| Q101241961 | Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting |
| Q33928837 | Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer |
| Q33699376 | Does the timing of esophagectomy after chemoradiation affect outcome? |
| Q84165636 | Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma |
| Q47346404 | Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial |
| Q52908863 | Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? |
| Q38558908 | Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection |
| Q100430667 | Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy |
| Q83131611 | Esophageal tumor length is independently associated with long-term survival |
| Q92680019 | Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma |
| Q54498016 | Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. |
| Q35667565 | Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma |
| Q47312339 | HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells |
| Q42030667 | Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties |
| Q84362290 | Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma |
| Q34332847 | Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. |
| Q51754931 | Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer |
| Q49012537 | Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance |
| Q45844685 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus |
| Q47318997 | Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial |
| Q44893920 | Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation |
| Q37333641 | Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies |
| Q43267597 | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
| Q42557385 | Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma |
| Q80514902 | Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma |
| Q92130607 | Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma |
| Q37104321 | Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors |
| Q34973844 | MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus |
| Q98782021 | Modified En bloc Esophagectomy Compared to Standard Resection after Neoadjuvant Chemoradiation |
| Q82974884 | Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins |
| Q53665053 | Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. |
| Q38669772 | Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. |
| Q37320833 | Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation |
| Q88236253 | Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma |
| Q33389221 | Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury |
| Q39844954 | Pathologic T0N1 Esophageal Cancer After Neoadjuvant Therapy and Surgery: An Orphan Status |
| Q47275072 | Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience |
| Q39148022 | Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. |
| Q38690078 | Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. |
| Q33770008 | Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome |
| Q35129698 | Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy |
| Q44998863 | Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. |
| Q80649120 | Proposed modification of nodal status in AJCC esophageal cancer staging system |
| Q53211562 | Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. |
| Q54508831 | Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. |
| Q84867779 | Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma |
| Q92474379 | Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? |
| Q87412469 | Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation |
| Q92434462 | Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma |
| Q92434912 | Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma |
| Q89970087 | Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients |
| Q43593864 | The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma |
| Q43870702 | The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma |
| Q91348069 | Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation |
| Q43167565 | Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction |
| Q37778969 | Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases |
| Q47135563 | Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. |
Search more.